Clinical Trials Logo

Stroke clinical trials

View clinical trials related to Stroke.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT03292159 Suspended - Stroke Clinical Trials

Transcutaneous Vagus Nerve Stimulation for Motor Recovery After Stroke

Start date: May 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and effectiveness of Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) for improving motor recovery after stroke. Subacute stroke patients will receive RAVANS or sham stimulation concurrent with arm motor training during 10 intervention sessions occurring daily for 30 minutes over 2 weeks. The safety and improvements in arm motor function after the intervention will be compared in patients receiving RAVANS to those receiving sham stimulation.

NCT ID: NCT03202147 Suspended - Ischemic Stroke Clinical Trials

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Start date: July 2016
Phase: Phase 2
Study type: Interventional

This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.

NCT ID: NCT03098732 Suspended - Stroke, Acute Clinical Trials

Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.

NCT ID: NCT02950181 Suspended - Stroke Clinical Trials

Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients

Start date: July 29, 2014
Phase: N/A
Study type: Interventional

This study involves looking at Cerebral oximetry measurements in pediatric and neonatal patients who are experiencing a critical illness. Such as Altered mental status, seizures, trauma, sepsis, etc.

NCT ID: NCT02773888 Suspended - Stroke Clinical Trials

An Evaluation of Non-Invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an Intraparenchymal Pressure Monitoring Device

Start date: December 2015
Phase: N/A
Study type: Interventional

Invasive intracranial pressure (ICP) monitoring is highly effective, but involves risks. HS-1000 measures ICP non-invasively by assessing the acoustic properties of the patient's head. HS-1000 device, a proprietary non-invasive ICP monitor, is expected to safely and accurately monitor ICP with minimal discomfort to patients, and provide information about normal or elevated ICP levels to the physicians.

NCT ID: NCT02533778 Suspended - Ischemic Stroke Clinical Trials

ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization

Start date: July 2015
Phase: N/A
Study type: Interventional

A prospective pilot study to evaluate the recanalization and safety of mechanical thrombectomy through a cerebral angiogram in patients with stroke symptoms last seen normal between 8 - 24 hours.

NCT ID: NCT02460484 Suspended - Clinical trials for Perinatal Arterial Ischemic Stroke

Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous human umbilical cord blood (hUCB) stored at Cord Blood Registry will be given to children who have suffered from a Perinatal Arterial Ischemic Stroke. The aim is to determine if hUCB infusion is safe, if late functional outcome is improved, if hUCB treatment improves physiologic response in the child's SSEP & EEG, and the effect of hUCB infusion in altering anatomic findings on MRI.

NCT ID: NCT02401698 Suspended - Stroke Clinical Trials

Exploring Cerebellar Inhibition of the Motor Cortex in Stroke Patients

Start date: December 2014
Phase: N/A
Study type: Observational

The past 10 years of research in post stroke patients have shown certain types of rehabilitation can help neuronal plasticity of the brain. Transcranial magnetic stimulation (TMS) can be used to monitor this plasticity by mapping the brain's function (measuring brain activity). Recent research suggests that TMS can be used for both prognosis (determining future function) and to determine what type of rehabilitation therapy will work best after stroke. The purposes of this research study are to: 1) determine changes in cerebellar activity after motor cortical stroke 2) compare changes in recovery of motor function with changes in cerebellar - motor cortex connections; 3) determine the ability of TMS to "predict" functional outcome after stroke. The primary hypotheses are: 1) functional recovery will be correlated with TMS changes (as measure of motor threshold (MT), intracortical inhibition, cerebellar cerebral inhibition (CBI), motor evoked potentials (MEPs) and recruitment curves; 2) baseline TMS will predict future functional outcomes.

NCT ID: NCT02059785 Suspended - Ischemic Stroke Clinical Trials

Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke

Start date: June 2013
Phase: Phase 2
Study type: Interventional

This research is a Randomized, double-blind, placebo-controlled, multicenter clinical study. Chinese subjects with Ischemic Stroke.

NCT ID: NCT01852201 Suspended - Ischemic Stroke Clinical Trials

POSITIVE Stroke Clinical Trial

Start date: September 2013
Phase: N/A
Study type: Interventional

Primary Endpoint: The primary objective is to show that AIS patients, ineligible for or refractory to treatment with IV-tPA, with appropriate image selection, treated with mechanical thrombectomy within 6-12 hours of symptom onset have less stroke related disability and improved good functional outcomes as compared to those treated with best MT with respect to endpoint defined as: • 90-day global disability assessed via the modified Rankin score (mRS), analyzed using raw mRS scores. Statistical details can be found in section 7.2. Secondary Endpoints: - 90-day global disability in the 6-12 hr cohort assessed via the overall distribution of mRS - Proportion of patients with good functional recovery for the 6-12 hr cohort as defined by mRS 0-2 at 90 days - Mortality at 30 and 90 days - Intracranial hemorrhage with neurological deterioration (NIHSS worsening >4) within 24 hours of randomization - Procedure related serious adverse events (SAE's) - Arterial revascularization measured by TICI 2b or 3 following device use